Can Peptides Help Treat Astigmatism?

A trend involving the self-administration of the peptide elamipretide, also known as SS-31, has emerged across social media platforms, with users claiming the substance can improve vision and correct structural eye issues. However, ophthalmologists and medical experts warn that there is no clinical evidence to support these claims, and the practice of injecting these compounds without medical oversight poses significant safety risks.

The interest in SS-31 has surged on TikTok, where users have shared anecdotal reports of improved eyesight. Some individuals claim the peptide has reduced their sensitivity to blue light and computer screens, while others assert it has improved their ability to focus.

Among the most specific claims circulating in digital forums is that SS-31 can treat astigmatism. Some users have reported that after several months of use, their vision improved and their astigmatism disappeared. One user claimed their vision improved by .25 and that they no longer had astigmatism after three months of use.

Medical Evidence and FDA Status

Despite the viral claims, medical professionals state that the science does not support the use of SS-31 for common refractive errors. Astigmatism is a structural irregularity of the eye, and there is no widely accepted medical evidence to suggest that peptide injections can reshape the cornea or correct the refractive errors associated with the condition.

The SS-31 peptide is technically FDA-approved, but only for a very specific and limited purpose: the treatment of Barth syndrome, a rare mitochondrial disease. It is not approved for the treatment of nearsightedness (myopia), presbyopia, or astigmatism.

Research into the peptide’s potential for other ocular conditions has also been unsuccessful. Recent studies investigating whether SS-31 could protect the retina or treat age-related macular degeneration found the drug to be ineffective for those purposes.

The Rise of Performance Peptides

This trend is part of a broader intersection between biohacking culture and ocular health. Peptides, which are short chains of amino acids, have gained popularity in athletic and wellness communities for perceived roles in tissue repair and physical optimization. This fascination has expanded into attempts to enhance sensory functions and visual acuity.

Many of the peptides currently sought after by wellness enthusiasts are restricted. Some are listed on the FDA’s Category 2 bulk substance list, meaning they are not eligible for compounding by compounding pharmacies.

Risks and Professional Guidance

Experts emphasize that the mechanism of action for SS-31 is not designed to address the optical and structural issues that cause most vision problems. Self-administering these substances without professional medical supervision presents significant risks to long-term health and patient safety.

The rise in myopia is a documented public health concern, with cases expected to increase as more people spend time indoors and use screens. However, ophthalmologists stress that the only safe and effective way to address vision concerns is through a comprehensive eye exam performed by a licensed professional, rather than following viral supplement trends.

The claim that an injected peptide can correct this structural irregularity is a significant medical assertion that requires rigorous clinical validation. Currently, there is no widely accepted medical evidence to support the idea that peptide injections can reshape the cornea or correct the refractive errors associated with astigmatism.

World Today Journal